Format

Send to

Choose Destination
Ann N Y Acad Sci. 2004 Jun;1022:286-94.

Cancer proteomics: Serum diagnostics for tumor marker discovery.

Author information

1
Department of Pathology, Division of Clinical Chemistry, and Center for Biomarker Discovery, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. arai@jhmi.edu

Abstract

Cancer proteomics is an exciting field that is witnessing many new developments in recent years. It is hoped that these advances will result in decreased cancer death rates, which have not declined dramatically in the last several decades. Some of the problems with current tumor markers include the lack of sensitivity and specificity, factors that prevent their use in population-based screening of disease. Thus, there is an urgent need to identify novel biomarkers that can faithfully detect the disease state. As we are now in the post-genome era, many opportunities have been created. Genomic sequence data are available for human, as well as several other species. We are now poised to mine these data and to determine the functions of the encoded proteins constituting the human genome. Proteomics affords this opportunity by providing enhanced procedures and tools for discovery and also a framework for understanding these components in terms of pathogenesis. New technologies and improvements in existing methodologies will allow for the rapid growth in the identification and characterization of peptides and proteins that are unique to various clinical states. This technology can be successfully applied to clinical specimens for the identification of new tumor markers.

PMID:
15251974
DOI:
10.1196/annals.1318.044
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center